Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 5/2015

01-06-2015 | Original Article

Assessment of the prognostic capacity of pretreatment, interim, and post-therapy 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type

Authors: Chong Jiang, Xin Zhang, Ming Jiang, Liqun Zou, Minggang Su, Russell Oliver Kosik, Rong Tian

Published in: Annals of Nuclear Medicine | Issue 5/2015

Login to get access

Abstract

Objective

Although the prognostic value of positron emission tomography/computed tomography (PET/CT) using [18F]-fluorodeoxyglucose (18F-FDG) has been widely confirmed for diffuse large B cell lymphoma, its value for extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), is still controversial. Therefore, we designed a prospective study to investigate the prognostic value of 18F-FDG PET/CT in patients with ENKTL.

Materials and methods

Thirty-three patients with newly diagnosed, untreated ENKTL, were enrolled in this study. Interim and post-therapy PET/CT scans were analyzed by visual evaluation, in accordance with the criteria set forth by the International Harmonization Project. Patients were classified as either positive or negative. Pretreatment maximum standardized uptake values (SUVmax) of 18F-FDG were recorded in the most 18F-FDG-intense lesions. The pretreatment 18F-FDG SUV as well as the interim and post-therapy PET/CT results were assessed for the ability to predict progression-free survival (PFS) and overall survival (OS).

Results

On the pretreatment scan, the SUVmax of the indicator lesion was >10.00 in 81.8 % of patients who were treatment-resistant and ≤10.00 in 86.4 % of patients who were treatment non-resistant (mean SUVmax, 12.93 and 8.10, respectively). Univariate analyses revealed that pretreatment SUVmax is a significant predictor (P < 0.01, P < 0.01) of PFS and OS, respectively. Multivariate analyses revealed that pretreatment SUVmax (P < 0.01, P = 0.01) and post-therapy PET/CT result (P < 0.01, P = 0.04) are independent predictors of PFS and OS, respectively.

Conclusions

18F-FDG uptakes prior to treatment and post-therapy PET/CT results can predict unfavorable outcomes following treatment in patients with ENKTL, but interim PET/CT results have little value in predicting survival.
Literature
1.
Swerdlow SH. International Agency for Research on Cancer. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008.
2.
Peh SC. Host ethnicity influences non-Hodgkin’s lymphoma subtype frequency and Epstein–Barr virus association rate: the experience of a multi-ethnic patient population in Malaysia. Histopathology. 2001;38:458–65.PubMedCrossRef
3.
Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST, et al. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10:1093–101.PubMedCrossRef
4.
Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110:3507–16.PubMedCrossRef
5.
Kim CY, Hong CM, Kim DH, Son SH, Jeong SY, Lee SW, et al. Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on (1)(8)F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma. Eur J Nucl Med Mol Imaging. 2013;40:1321–9.PubMedCrossRef
6.
Khong PL, Huang B, PhinLee EY, SumChan WK, Kwong YL. Midtreatment 18F-FDG PET/CT scan for early response assessment of SMILE therapy in natural killer/T-cell lymphoma: a prospective study from a single center. J Nucl Med. 2014;55:911–6.PubMedCrossRef
7.
Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(Suppl 1):11S–20S.PubMedCrossRef
8.
Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med. 2011;52:386–92.PubMedCentralPubMedCrossRef
9.
Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma. J Clin Oncol. 2007;25:571–8.PubMedCrossRef
10.
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.PubMed
11.
Li YJ, Li ZM, Xia XY, Huang HQ, Xia ZJ, Lin TY, et al. Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas. J Nucl Med. 2013;54:507–15.PubMedCrossRef
12.
Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Br J Haematol. 2001;115:793–800.PubMedCrossRef
13.
Cahu X, Bodet-Milin C, Brissot E, Maisonneuve H, Houot R, Morineau N, et al. 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. Ann Oncol. 2011;22:705–11.PubMedCrossRef
14.
Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging. 2003;30(Suppl 1):S89–96.PubMedCrossRef
15.
Kim SJ, Kim WS. Treatment of localized extranodal NK/T cell lymphoma, nasal type. Int J Hematol. 2010;92:690–6.PubMedCrossRef
16.
Brepoels L, Stroobants S, Verhoef G. PET and PET/CT for response evaluation in lymphoma: current practice and developments. Leuk Lymphoma. 2007;48:270–82.PubMedCrossRef
Metadata
Title
Assessment of the prognostic capacity of pretreatment, interim, and post-therapy 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type
Authors
Chong Jiang
Xin Zhang
Ming Jiang
Liqun Zou
Minggang Su
Russell Oliver Kosik
Rong Tian
Publication date
01-06-2015
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 5/2015
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-015-0964-8

Other articles of this Issue 5/2015

Annals of Nuclear Medicine 5/2015 Go to the issue

Original Article

An exploratory efficacy study of the amyloid imaging agent [18F]flutemetamol in Japanese Subjects

Original Article

Nuclear myocardial perfusion imaging using thallium-201 with a novel multifocal collimator SPECT/CT: IQ-SPECT versus conventional protocols in normal subjects

Technical Note

Usefulness of the Chang attenuation correction method with use of a CT-based μ map by FBP reconstruction in 201Tl SPECT-MPI

Original Article

Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy

Original Article

Update on nodal staging in non-small cell lung cancer with integrated positron emission tomography/computed tomography: a meta-analysis

Original Article

Elastofibroma dorsi incidentally detected by 18F-FDG PET/CT imaging